Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Terminated × Hepatitis C × Clear all

Phase

Phase NA 1 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Neoplasms 13 Prostatic Neoplasms 11 Neoplasm Metastasis 10 Colorectal Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Polycystic Ovary Syndrome 7 Pain 7 Lung Neoplasms 7 Leiomyoma 6 Anemia 5 Skin Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Leukemia 4 Carcinoma, Renal Cell 4 Recurrence 3 Melanoma 3 Liver Neoplasms 3 Kidney Neoplasms 3 Keratosis, Actinic 3 Insulin Resistance 3 Carcinoma, Hepatocellular 3 Brain Neoplasms 3 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Stomach Neoplasms 2 Sleep Initiation and Maintenance Disorders 2

Interventions

ledipasvir, sofosbuvir drug combination 1 Sofosbuvir 1 Ribavirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡